Rigor Reviewed

Rigor-Reviewed Manuscript

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.

Name: Αlpha¹ Rigor Record — Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
Item: Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
Rating: 59
Author: Αlpha¹

Wong GL, Yuen MF, Lin B, Douglas MW, Hu P, Xie Q, Lv F, Tak WY, Leerapun A, Kim DJ, Tangkijvanich P, Lim YS, Dai CY, O'Beirne J, Weltman M, Khemnark S, Piratvisuth T, Manasirisuk W, Chen X, Liu CJ, Heo J, Lee J, Niu J, Kumar R, Kumar R, Zhu C, Cao K, Tian A, Chen X, Zhu Q, Margolis D, Jia J, Hong Z

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 3 high issues for “Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 5 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Study-design details incomplete (controls, blinding, power)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 2 trial with a clear scientific premise, appropriate statistical methods, and transparent reporting. The main weaknesses are the lack of justification for the open-label design, absence of a formal power analysis for the single-arm cohort, and a vague data availability statement.

Both reviewers classified the study as interventional, which is adopted. The evaluation covers all eight rigor dimensions; no dimensions were excluded as not applicable. The reviewers agreed on all dimensions except study design (one pass, one warn), where the synthesized judgment is 'warn' based on the preponderance of evidence.

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites prior studies on elebsiran and PEG-IFNα, acknowledges the lack of a monotherapy control in a prior study, and hypothesizes that BRII-179 responders may benefit more. Limitations of prior research are addressed by including a PEG-IFNα monotherapy control in part I.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes the scientific premise with prior work and a logical rationale.

Evidence

paraphrase[Introduction, paragraph 3]

“A prior study evaluating elebsiran in combination with PEG-IFNα reported an HBsAg loss rate of approximately 30% at the end of treatment (EOT) in participants with chronic HBV infection. However, this study lacked a PEG-IFNα monotherapy control, limiting direct comparison.”

direct quote[Introduction, paragraph 4]

“It was hypothesized that individuals with chronic HBV infection who were able to overcome HBV-induced immune dysfunction following exposure to BRII-179 may have an increased likelihood of mounting an effective immune response upon subsequent treatment with elebsiran and PEG-IFNα, potentially leading to higher rates of functional cure.”